Version 1
: Received: 22 August 2023 / Approved: 22 August 2023 / Online: 22 August 2023 (09:31:05 CEST)
How to cite:
Mushebenge, A.; Ugbaja, S.C.; Mbatha, N.A.; Khan, R.M.; Kumalo, H.M. Unravelling Insights into the Evolution and Management of SARS-CoV-2: A Comprehensive Review. Preprints2023, 2023081547. https://doi.org/10.20944/preprints202308.1547.v1
Mushebenge, A.; Ugbaja, S.C.; Mbatha, N.A.; Khan, R.M.; Kumalo, H.M. Unravelling Insights into the Evolution and Management of SARS-CoV-2: A Comprehensive Review. Preprints 2023, 2023081547. https://doi.org/10.20944/preprints202308.1547.v1
Mushebenge, A.; Ugbaja, S.C.; Mbatha, N.A.; Khan, R.M.; Kumalo, H.M. Unravelling Insights into the Evolution and Management of SARS-CoV-2: A Comprehensive Review. Preprints2023, 2023081547. https://doi.org/10.20944/preprints202308.1547.v1
APA Style
Mushebenge, A., Ugbaja, S.C., Mbatha, N.A., Khan, R.M., & Kumalo, H.M. (2023). Unravelling Insights into the Evolution and Management of SARS-CoV-2: A Comprehensive Review. Preprints. https://doi.org/10.20944/preprints202308.1547.v1
Chicago/Turabian Style
Mushebenge, A., Rene M. Khan and Hezekiel M. Kumalo. 2023 "Unravelling Insights into the Evolution and Management of SARS-CoV-2: A Comprehensive Review" Preprints. https://doi.org/10.20944/preprints202308.1547.v1
Abstract
Worldwide, the COVID-19 pandemic, which was brought on by the brand-new coronavirus SARS-CoV-2, has claimed a sizable number of lives. Despite the urgency, COVID-19 does not have any particular antiviral treatments at this time. As a result, scientists are concentrating on repurposing already existing antiviral medications or creating brand-new ones. The SARS-CoV-2 main protease, which is necessary for viral replication, has been identified as a possible target for a family of medicines called main protease inhibitors (MPIs). Studies of the major proteases from SARS-CoV and MERS-CoV, which have remarkably similar structures and functions to SARS-CoV-2, have provided insight for the creation of MPIs. By analyzing the MPI trials for SARS-CoV and MERS-CoV, this review sheds light on the possible therapeutic uses of MPIs for COVID-19. The review talks about how MPIs work, how effective they are against SARS-CoV and MERS-CoV, and how safe they are. The paper also emphasizes current developments in the creation of MPIs for SARS-CoV-2, including as computational studies, in vitro and in vivo research, and clinical trials. According to the review, there is a lot of hope for MPIs in the treatment of COVID-19, and numerous medications are in the works. Although more research is needed to assess their safety and effectiveness in clinical settings, these medications may offer patients with COVID-19 a much-needed therapeutic option. The review also emphasizes the importance of ongoing research into the structure and function of the SARS-CoV-2 main protease, as this information will be critical for the development of effective MPIs and other antiviral drugs in the future.
Keywords
Main Protease Inhibitors; SARS-CoV-2; COVID-19; mutations; vaccines; therapeutics; drug repurposing; management strategies
Subject
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
